Incidence of COVID-19 in patients with rheumatic disease: is prior health education more important than shielding advice during the pandemic?

Author:

Kipps Sarah,Paul Anindita,Vasireddy Sreekanth

Abstract

AbstractThe COVID-19 pandemic has led to major changes in clinical practice on a global scale in order to protect patients. This includes the identification of vulnerable patients who should “shield” in order to reduce the likelihood of contracting SARS-CoV2. We used national specialty guidance and an adapted screening tool to risk stratify patients identified from our prescribing and monitoring databases, and identify those needing to shield (score ≥ 3) using information from departmental letters, online general practice records and recent laboratory investigations. We collated underlying rheumatological conditions and risk factors. Two months into the shielding process, we examined the COVID-19 status of these patients using hospital laboratory records and compared to population level data. Of 887 patients assessed, 248 (28%) scored ≥ 3 and were sent a standard shielding letter. The most common risk factor in the shielding letter group was age ≥ 70 years and/or presence of a listed co-morbidity (199 patients). The most common rheumatology conditions were rheumatoid arthritis (69.4%), polymyalgia rheumatica (8.5%) and giant cell arteritis (8.5%). Coronavirus incidence rates were similar in the shielding letter group (0.403%) and in the UK population (0.397%). However, we found a trend towards lower incidence (0.113%) in our whole cohort (RR 0.28, 95%CI 0.04–2.01 for the whole cohort compared to UK population). The trend towards lower incidence in this cohort could be because of prior education regarding general infection risk and response to public health messages. While risk stratification and shielding could be effective, prior education regarding general infection risk and public health messages to enhance health protection behaviours during a pandemic may have equal or more important roles. Key PointsPatients on treatment for rheumatic disorders showed a trend for lower incidence of COVID-19 transmission irrespective of shielding letter statusThis could potentially be because of prior education regarding infection risk received when starting on disease-modifying medicationHealth education influencing health protection behaviours may be of equal or more importance than shielding information in reducing transmission of SARS-CoV-2

Funder

University of Manchester

Publisher

Springer Science and Business Media LLC

Subject

General Medicine,Rheumatology

Reference11 articles.

1. Public Health England. Guidance on shielding and protecting people who are clinically extremely vulnerable from COVID-19. https://www.gov.uk/government/publications/guidance-on-shielding-and-protecting-extremely-vulnerable-persons-from-covid-19/guidance-on-shielding-and-protecting-extremely-vulnerable-persons-from-covid-19 (accessed 27/05/2020).

2. Price E, Macphie E, Kay L et al (2020) Identifying rheumatic disease patients at high risk and requiring shielding during the COVID-19 pandemic. Clin Med 20(3):256–261. https://doi.org/10.7861/clinmed.2020-01492020

3. Public Health England. Coronavirus (COVID-19) in the UK. https://coronavirus.data.gov.uk/#category = utlas&map = case (accessed 27/05/2020).

4. National Office of Statistics. Overview of the UK population: August 2019. https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationestimates/articles/overviewoftheukpopulation/august2019 (accessed 28/05/2020)

5. Bolton Council. Planning and Research People in Bolton Factfile no. 1, 2018 Population Estimates. https://www.bolton.gov.uk/downloads/file/2285/2018-population-estimates-factfile-updated-july-2019-(accessed 27/05/2020)

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3